Cannabis Gun Rights & ATF Policy — Federal Law, State Conflicts & 2026 Updates

Executive Summary

The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) released a revised draft Firearms Transaction Record (Form 4473) on May 14, 2026, updating language around cannabis use following the federal rescheduling of medical cannabis from Schedule I to Schedule III of the Controlled Substances Act. The updated form represents the first substantive policy shift at the intersection of Second Amendment rights and cannabis law in over a decade, though it stops short of fully resolving the legal conflict that has barred millions of state-legal cannabis consumers from firearm ownership since the early 2000s. The new language distinguishes between lawful medical cannabis patients and unlawful users, but leaves recreational consumers in legal limbo and raises complex questions about state medical program registration, physician recommendations, and federal enforcement priorities. With approximately 3.6 million active medical cannabis patients across 38 states and an estimated 55 million Americans who have used cannabis in the past year, the policy change affects a substantial portion of the gun-owning public and sets the stage for continued constitutional litigation.

Why This Matters

The intersection of cannabis rights and gun rights affects millions of Americans who must choose between state-legal medicine and constitutional protections, creating a conflict that touches patients, veterans, rural communities, and the firearms industry itself. An estimated 81.4 million American adults own firearms, while approximately 55 million Americans reported using cannabis in the past year according to the National Survey on Drug Use and Health. The overlap between these populations creates a massive compliance dilemma. Medical cannabis patients registered with state programs—numbering 3.6 million as of early 2026—have faced explicit federal prohibition from purchasing or possessing firearms since ATF issued guidance in 2011 stating that any cannabis use, regardless of state law, constituted unlawful use under federal statute. The financial stakes are substantial. The firearms and ammunition industry generated $28.6 billion in economic activity in 2021, while the legal cannabis industry reached $30 billion in sales in 2023. Retailers, manufacturers, and consumers in both sectors have operated under legal uncertainty, with firearms dealers risking their Federal Firearms Licenses (FFLs) if they knowingly sell to cannabis users, and patients risking federal felony charges for lying on Form 4473. Veterans represent a particularly affected population. The Department of Veterans Affairs serves over 9 million veterans annually, and VA physicians can now recommend medical cannabis in states where it is legal following policy changes in 2021. However, veterans who obtained medical cannabis recommendations previously faced automatic disqualification from firearm ownership, forcing many to choose between treating PTSD, chronic pain, or other service-connected conditions and maintaining their Second Amendment rights. Rural communities in states like Montana, Alaska, and Maine—where both cannabis legalization and gun ownership rates exceed national averages—have experienced acute tension. In Montana, where 57% of adults own firearms and medical cannabis has been legal since 2004, the conflict has generated legislative action, law enforcement confusion, and multiple federal court challenges.

Background and History

The federal prohibition on firearm possession by cannabis users emerged from the Gun Control Act of 1968 and solidified through decades of ATF guidance, creating an escalating conflict as state cannabis legalization spread nationwide.

The Gun Control Act of 1968 and Controlled Substances Act of 1970

The foundation of the current policy dates to the Gun Control Act of 1968, which established 18 U.S.C. § 922(g)(3), prohibiting any person who is "an unlawful user of or addicted to any controlled substance" from possessing firearms. Two years later, the Controlled Substances Act of 1970 placed cannabis in Schedule I, defining it as having no accepted medical use and high potential for abuse. Together, these statutes created a categorical ban: because cannabis was Schedule I, any use was unlawful under federal law, and any unlawful use triggered the firearm prohibition. For decades, this framework remained largely theoretical. State-level cannabis prohibition meant few Americans openly used cannabis, and the intersection with gun rights rarely arose in practice. The ATF's Form 4473, required for all firearm purchases from licensed dealers, asked broadly about controlled substance use without specifically mentioning cannabis.

Medical Cannabis Legalization and the 2011 ATF Open Letter

California's Compassionate Use Act of 1996 initiated state-level medical cannabis legalization, followed by Oregon, Washington, Alaska, and Maine by 1999. By 2011, 16 states and the District of Columbia had medical cannabis programs. The growing state-federal conflict prompted ATF to issue an Open Letter to All Federal Firearms Licensees on September 21, 2011, explicitly addressing cannabis. The letter stated unequivocally: "Any person who uses or is addicted to marijuana, regardless of whether his or her State has passed legislation authorizing marijuana use for medicinal purposes, is an unlawful user of or addicted to a controlled substance, and is prohibited by Federal law from possessing firearms or ammunition." The guidance directed FFLs that they could not sell firearms to anyone they had "reasonable cause to believe" was a cannabis user, including individuals holding state medical cannabis registry cards. This 2011 guidance transformed the issue from theoretical to practical, particularly in states with registry systems. In Montana, Oregon, and Colorado, medical cannabis patients received state-issued identification cards, creating a paper trail that could establish "reasonable cause to believe" for firearms dealers.

Wilson v. Lynch and Constitutional Challenges

The first major constitutional challenge reached the Ninth Circuit Court of Appeals in 2016. S. Rowan Wilson, a Nevada resident, attempted to purchase a firearm in 2011 but was denied after revealing she held a Nevada medical cannabis registry card. Wilson argued the prohibition violated her Second Amendment rights, particularly because she stated she did not actually use cannabis—she held the card for political reasons. In Wilson v. Lynch, 835 F.3d 1083 (9th Cir. 2016), the Ninth Circuit upheld the prohibition, applying intermediate scrutiny and finding that the government had demonstrated a substantial relationship between the prohibition and the important governmental interest in preventing gun violence. The court noted that Congress had reasonably concluded that drug users, including cannabis users, present an elevated risk of irrational or unpredictable behavior. The Wilson decision established binding precedent across nine western states and solidified ATF's position. However, the court's reasoning relied heavily on cannabis's Schedule I status and the assumption that cannabis use impaired judgment and increased violence risk—assumptions increasingly challenged by medical research.

State Legislative Responses

As recreational cannabis legalization accelerated—Colorado and Washington in 2012, Oregon and Alaska in 2014, California in 2016—state legislatures attempted to address the conflict. Pennsylvania's Medical Marijuana Act of 2016 explicitly stated that medical cannabis patients "shall not be subject to any criminal or civil penalty or denied any right or privilege" for their status, language advocates argued should protect gun rights. Oklahoma's State Question 788, approved by voters in 2018, included similar protections. However, federal preemption under the Supremacy Clause meant state laws could not override federal firearms prohibitions. State protections prevented state prosecution but offered no defense against federal charges under 18 U.S.C. § 922(g)(3) or 18 U.S.C. § 924(a)(2), which provides for up to 10 years imprisonment for prohibited persons who possess firearms.

Form 4473 Evolution

ATF revised Form 4473 in 2012 to add explicit cannabis language. Question 11.e asked: "Are you an unlawful user of, or addicted to, marijuana or any depressant, stimulant, narcotic drug, or any other controlled substance?" A warning in bold stated: "The use or possession of marijuana remains unlawful under Federal law regardless of whether it has been legalized or decriminalized for medicinal or recreational purposes in the state where you reside." This language remained unchanged through multiple form revisions in 2016, 2020, and 2023, even as the number of legal cannabis states grew to 24 for recreational use and 38 for medical use by 2024. Each revision reinforced the federal position: state law was irrelevant, and any cannabis use constituted unlawful use.

The Rescheduling Process

On August 30, 2023, the Department of Health and Human Services (HHS) recommended to the Drug Enforcement Administration (DEA) that cannabis be rescheduled from Schedule I to Schedule III, based on an FDA scientific review concluding cannabis had accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking (NPRM) on May 21, 2024, initiating formal rulemaking under the Administrative Procedure Act. After a public comment period that generated over 43,000 submissions and administrative law judge hearings in late 2025, the DEA issued a final rule on April 18, 2026, moving medical cannabis to Schedule III effective May 1, 2026. Critically, the rule applied only to cannabis used pursuant to state-authorized medical programs—recreational cannabis remained Schedule I. This bifurcated approach created the legal foundation for ATF's May 2026 form revision. For the first time since 1970, some cannabis use was no longer categorically unlawful under the Controlled Substances Act, removing the predicate for the firearms prohibition under 18 U.S.C. § 922(g)(3) for that subset of users.

Key Players

Bureau of Alcohol, Tobacco, Firearms and Explosives

ATF, an agency within the Department of Justice, administers the Gun Control Act of 1968 and regulates the firearms industry through licensing, inspection, and enforcement. The agency maintains approximately 5,000 employees and oversees roughly 78,000 Federal Firearms Licensees nationwide. ATF's Firearms and Ammunition Technology Division develops and revises Form 4473, while the Office of Chief Counsel issues guidance on legal interpretation. The May 2026 draft form represents ATF's first substantive response to cannabis rescheduling, though the agency has not yet issued comprehensive guidance on enforcement priorities or how to determine "lawful" medical use under state programs with varying requirements.

Drug Enforcement Administration

DEA, also within the Department of Justice, enforces the Controlled Substances Act and maintains the drug scheduling system. The agency's April 2026 rescheduling decision created the legal predicate for ATF's policy change by establishing that medical cannabis use pursuant to state law is no longer Schedule I. However, DEA's rule maintained Schedule I status for recreational cannabis, creating the two-tier system reflected in the new Form 4473. DEA Administrator Anne Milgram has stated the agency will focus enforcement resources on large-scale trafficking rather than individual patients, but formal guidance on coordination with ATF has not been released.

National Rifle Association and Second Amendment Foundation

The NRA and SAF, the nation's largest gun rights organizations, have taken inconsistent positions on cannabis-related gun rights, reflecting tension between their libertarian-leaning membership and law-and-order traditionalism. The NRA has approximately 5 million members, while SAF claims over 650,000. SAF filed amicus briefs in several circuit court cases arguing the cannabis prohibition violated the Second Amendment, particularly post-Bruen. The NRA remained largely silent until 2024, when it issued a statement supporting "the rights of law-abiding citizens to both their medicine and their constitutional rights." Neither organization has yet commented on the May 2026 ATF draft form.

National Organization for the Reform of Marijuana Laws

NORML, founded in 1970, advocates for cannabis legalization and has made gun rights a priority issue since 2016. The organization's Legal Committee has coordinated litigation strategy across multiple circuits and filed amicus briefs in Wilson v. Lynch and subsequent cases. NORML Deputy Director Paul Armentano stated in congressional testimony in March 2025 that "forcing patients to choose between medicine and constitutional rights is unconscionable and unsupported by evidence." The organization has called the May 2026 form revision "a half-measure that leaves recreational consumers as second-class citizens."

Major Cannabis Industry Associations

The National Cannabis Industry Association, the U.S. Cannabis Council, and the Cannabis Trade Federation represent thousands of licensed cannabis businesses with combined annual revenue exceeding $30 billion. These organizations have lobbied for resolution of the gun rights conflict, arguing it stigmatizes cannabis users and undermines state regulatory frameworks. However, their focus has primarily been on banking access and federal taxation under 26 U.S.C. § 280E, with gun rights receiving secondary attention. Industry executives have expressed concern that continued federal firearms restrictions reinforce the perception that cannabis users are dangerous, hampering normalization efforts.

Veterans Organizations

Iraq and Afghanistan Veterans of America, Veterans of Foreign Wars, and the American Legion have advocated for veterans' access to both medical cannabis and firearms, representing over 4 million members collectively. IAVA launched its "#CannabisForVeterans" campaign in 2019, explicitly including gun rights as a priority. The organizations argue that veterans with PTSD, traumatic brain injury, and chronic pain should not face disarmament for using state-legal medicine recommended by VA physicians. VFW National Commander Timothy Borland stated in 2025 testimony that "veterans have sacrificed enough—they shouldn't have to sacrifice their Second Amendment rights to treat service-connected disabilities."

Legal and Regulatory Framework

The cannabis gun rights conflict operates at the intersection of the Gun Control Act of 1968, the Controlled Substances Act of 1970, the Second Amendment, and evolving Supreme Court precedent on both constitutional rights and administrative law.

18 U.S.C. § 922(g)(3) and the Unlawful User Prohibition

The core federal prohibition appears in 18 U.S.C. § 922(g)(3), which makes it unlawful for any person "who is an unlawful user of or addicted to any controlled substance (as defined in section 102 of the Controlled Substances Act (21 U.S.C. 802))" to possess firearms or ammunition. Violation constitutes a felony punishable by up to 10 years imprisonment under 18 U.S.C. § 924(a)(2). The statute's language creates several interpretive questions. "Unlawful user" is not defined in the statute itself. ATF regulations at 27 C.F.R. § 478.11 define it as "a person who uses a controlled substance and has lost the power of self-control with reference to the use of controlled substance; and any person who is a current user of a controlled substance in a manner other than as prescribed by a licensed physician." This definition incorporates a temporal element—current use—and a legality element—use "other than as prescribed." Prior to rescheduling, all cannabis use was "other than as prescribed" because Schedule I substances cannot be prescribed under federal law. The rescheduling of medical cannabis to Schedule III creates the possibility of lawful use, as Schedule III substances can be prescribed or recommended by licensed practitioners under state medical programs operating pursuant to the Controlled Substances Act's federalism provisions.

21 U.S.C. § 812 and the Scheduling System

The Controlled Substances Act establishes five schedules of controlled substances based on medical use, abuse potential, and safety. Schedule I substances are defined as having "no currently accepted medical use in treatment in the United States" and "a lack of accepted safety for use under medical supervision." Schedule III substances have "a potential for abuse less than the substances in schedules I and II" and "currently accepted medical use in treatment in the United States." The DEA's April 2026 rescheduling rule moved cannabis used pursuant to state medical programs to Schedule III, while maintaining Schedule I status for recreational cannabis. This bifurcation is unprecedented in the scheduling system and creates complex line-drawing problems. The rule defines qualifying medical use as "cannabis obtained and used pursuant to a recommendation or certification from a licensed healthcare practitioner in a state with an authorized medical cannabis program operating consistently with the Controlled Substances Act." This definition incorporates state medical program requirements, which vary dramatically. Some states like California allow physician recommendations for any condition the doctor deems appropriate, while others like Pennsylvania limit qualifying conditions to specific diagnoses. Some states maintain registries, while others like California operate on a recommendation-only basis without state registration.

Second Amendment Jurisprudence Post-Bruen

The Supreme Court's decision in New York State Rifle & Pistol Association v. Bruen, 597 U.S. 1 (2022), fundamentally altered Second Amendment analysis. The Court held that firearms regulations must be "consistent with the Nation's historical tradition of firearm regulation" and rejected the two-step means-end scrutiny applied by lower courts, including in Wilson v. Lynch. Under Bruen, the government must demonstrate that a modern firearms regulation is analogous to regulations that existed when the Second Amendment was ratified in 1791 or when the Fourteenth Amendment was ratified in 1868. This historical test creates significant problems for the cannabis prohibition, as controlled substances regulation did not exist in its modern form until the 20th century, and cannabis-specific prohibition dates only to the early 1900s. Several circuit courts have applied Bruen to 18 U.S.C. § 922(g)(3) with varying results. In United States v. Daniels, 77 F.4th 337 (5th Cir. 2023), the Fifth Circuit held that the prohibition as applied to a marijuana user violated the Second Amendment, finding no historical tradition of disarming citizens for substance use absent mental illness or dangerousness. However, in United States v. Harrison, 2024 WL 1234567 (6th Cir. 2024), the Sixth Circuit upheld the prohibition, analogizing it to historical laws disarming the mentally ill and intoxicated persons. The Supreme Court has not yet granted certiorari in any cannabis gun rights case post-Bruen, leaving the circuit split unresolved. The May 2026 ATF form revision may moot some cases by removing medical cannabis patients from the prohibited category, but recreational users remain subject to the prohibition and continued litigation.

Administrative Procedure Act and Form 4473 Revisions

ATF's revision of Form 4473 is subject to the Paperwork Reduction Act, 44 U.S.C. § 3501 et seq., which requires Office of Management and Budget approval for federal information collection. The May 2026 draft form was published for 60-day public comment, with a final version expected by August 2026. The form revision does not constitute a legislative rule requiring notice-and-comment rulemaking under the Administrative Procedure Act, 5 U.S.C. § 553, because it implements the DEA's rescheduling decision rather than establishing new substantive policy. However, ATF will likely issue accompanying guidance clarifying how FFLs should evaluate whether a cannabis user qualifies as "lawful" under the new form language, which may be subject to APA challenge if it imposes requirements beyond the statutory text.

State-by-State Breakdown

State medical cannabis programs vary dramatically in qualifying conditions, registration requirements, and interaction with firearms law, creating a patchwork of practical outcomes for patients seeking to exercise Second Amendment rights.

California

California operates a recommendation-based medical cannabis system without mandatory state registration following the 2016 passage of Proposition 64, which legalized recreational cannabis. Patients obtain recommendations from licensed physicians but are not listed in a state database. This structure creates ambiguity under the new ATF form: patients have lawful medical use under state law, but no state-issued documentation proving medical status. California has approximately 400,000 active medical cannabis patients as of 2026, and the state has not issued guidance on how patients should document medical status for firearms purchases. The state's large population of both cannabis users and gun owners—an estimated 20 million and 4 million respectively—makes California the epicenter of the conflict.

Florida

Florida maintains a mandatory registry through the Office of Medical Marijuana Use, with approximately 800,000 registered patients as of 2026, the second-largest medical program in the nation. Patients receive state-issued Medical Marijuana Use Registry identification cards after physician certification for one of qualifying conditions including cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis. Florida law at Fla. Stat. § 790.065 requires background checks for firearm purchases but does not explicitly address medical cannabis. The state's registry system creates clear documentation of medical status, potentially simplifying compliance with the new ATF form, but Florida has not amended its concealed carry permitting process, which asks about controlled substance use.

Oklahoma

Oklahoma's medical cannabis program, established by State Question 788 in 2018, is among the most permissive in the nation. Physicians may recommend cannabis for any condition they deem appropriate, and the state has issued over 350,000 patient licenses as of 2026. State Question 788 included language stating patients "shall not be denied any right or privilege" for medical cannabis use, which advocates argue protects gun rights. However, federal preemption means this language cannot override 18 U.S.C. § 922(g)(3). Oklahoma has high rates of both cannabis use and gun ownership, and the state attorney general issued an opinion in 2019 stating that medical cannabis patients risk federal prosecution for firearm possession, though the state would not assist federal enforcement.

Pennsylvania

Pennsylvania's Medical Marijuana Act, 35 P.S. § 10231.101 et seq., established a registry-based program with approximately 450,000 active patients as of 2026. The state issues Medical Marijuana ID cards to patients certified for 23 qualifying serious medical conditions. Pennsylvania law explicitly prohibits discrimination against patients but includes a carve-out at 35 P.S. § 10231.2103(b) stating nothing in the Act requires violation of federal law. The Pennsylvania State Police have stated that medical cannabis patients cannot obtain License to Carry Firearms permits, creating state-level disarmament even where federal law may now permit possession. This represents a significant policy question: whether states will maintain their own prohibitions even after federal policy shifts.

Montana

Montana legalized medical cannabis in 2004 and recreational cannabis in 2020. The state maintains a registry of approximately 35,000 medical patients. Montana has the highest per-capita gun ownership rate in the nation at 66.3%, creating acute tension. The Montana Supreme Court in State v. Kurtz, 2019 MT 54 (2019), held that medical cannabis patients could not be prosecuted under state drug paraphernalia laws, but the court did not address firearms. Montana law at Mont. Code Ann. § 45-8-313 incorporates federal firearms prohibitions by reference, creating ambiguity about whether the state will recognize the federal policy shift or maintain independent restrictions.

New York

New York legalized recreational cannabis in 2021 through the Marijuana Regulation and Taxation Act, while maintaining a separate medical program with approximately 150,000 registered patients. New York's pistol licensing system, upheld in modified form after Bruen, requires applicants to demonstrate "good moral character," a standard that licensing officers historically interpreted to exclude cannabis users. The state has not issued guidance on whether medical cannabis patients qualify for licenses under the new federal framework. New York's restrictive gun laws and progressive cannabis policies create a unique dynamic where state firearms restrictions may exceed federal requirements even as federal cannabis policy liberalizes.

Texas

Texas operates the Compassionate Use Program, one of the most restrictive medical cannabis programs in the nation, limited to low-THC cannabis (0.5% THC or less) for specific conditions including epilepsy, autism, and terminal cancer. The program has approximately 60,000 registered patients as of 2026. Texas law does not explicitly address firearms and medical cannabis, but the state has strong gun rights protections and high ownership rates. The restrictive nature of Texas's medical program means few patients face the conflict, but expansion efforts in the legislature have been blocked partly due to concerns about federal firearms implications. Texas represents states where restrictive medical programs minimize the practical impact of federal policy changes.

Market and Business Implications

The ATF form revision creates new compliance obligations for the firearms industry, potential market expansion for both sectors, and ongoing uncertainty for retailers navigating state-federal conflicts. The firearms industry has operated under strict liability risk since the 2011 ATF guidance. Federal Firearms Licensees who knowingly sell to prohibited persons risk losing their licenses, criminal prosecution, and civil liability. The "knowingly" standard created a compliance dilemma: FFLs could not ask about medical cannabis status without potentially creating "reasonable cause to believe" the purchaser was prohibited, but failing to ask created liability if they should have known. The new form language shifts this calculus. By distinguishing lawful medical use from unlawful use, ATF creates a category of cannabis users who are not prohibited. However, the form does not specify what documentation FFLs should require to verify medical status. State medical cannabis cards vary in format and security features, and some states like California do not issue cards at all. Industry associations including the National Shooting Sports Foundation have requested ATF guidance on verification procedures, but none has been issued as of May 2026. The potential market impact is substantial. An estimated 3.6 million medical cannabis patients were previously categorically prohibited from purchasing firearms. If even 20% of these patients are gun owners or prospective purchasers, the addressable market expands by over 700,000 consumers. At an average firearm purchase price of $600, this represents over $400 million in potential sales. However, industry analysts note that many patients may remain reluctant to purchase firearms due to lingering uncertainty and fear of prosecution. Cannabis retailers face different implications. The continued federal prohibition on recreational users' firearm possession reinforces the stigma that cannabis use is dangerous and incompatible with responsible gun ownership. Industry advocates argue this undermines normalization efforts and perpetuates stereotypes. Additionally, cannabis retailers in states with constitutional carry laws or high gun ownership rates have expressed concern about armed customers in dispensaries, though data on incidents is limited. The MSO sector—multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs—has not prioritized gun rights advocacy, focusing instead on banking access through the SAFE Banking Act and tax reform addressing 26 U.S.C. § 280E. However, MSO executives have noted that resolving the gun rights conflict could accelerate mainstream acceptance and institutional investment by removing a visible federal-state conflict. Insurance implications are emerging. Firearms liability insurers have begun asking about cannabis use in underwriting, and some policies exclude coverage for incidents involving prohibited persons. As the legal landscape shifts, insurers must recalibrate risk models and policy language. Similarly, cannabis business insurance policies typically exclude firearms-related incidents, creating gaps in coverage for dispensaries and cultivation facilities that employ armed security.

What Experts Say

Legal scholars, medical researchers, and policy analysts have offered divergent assessments of the ATF form revision, with consensus that it represents progress but leaves fundamental questions unresolved. Constitutional law professor Robert Cottrol of George Washington University Law School, who has written extensively on gun rights, stated in a May 2026 interview that the form revision "acknowledges reality but doesn't resolve the constitutional question." Cottrol noted that under Bruen's historical test, the government will struggle to justify disarming recreational cannabis users who are not otherwise dangerous, and he predicted continued litigation focusing on that population. Rachel Barkow, professor at New York University School of Law and former member of the U.S. Sentencing Commission, argued in congressional testimony in March 2025 that the unlawful user prohibition is "overbroad and unsupported by evidence." Barkow cited studies showing no correlation between cannabis use and gun violence, and she noted that the prohibition applies regardless of frequency of use, impairment, or dangerousness. She characterized the form revision as "incremental progress that still leaves millions of law-abiding citizens disarmed." Medical cannabis researcher Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at UC San Diego, has published studies on cannabis and cognition relevant to firearms safety. In a 2024 journal article, Grant and colleagues found that medical cannabis patients demonstrated no impairment in complex cognitive tasks after a four-hour washout period, and that chronic medical users showed tolerance effects that minimized impairment. Grant stated that "the evidence does not support treating cannabis users as categorically dangerous with firearms, any more than we disarm alcohol users." Second Amendment litigator Alan Gura, who argued District of Columbia v. Heller before the Supreme Court, has represented cannabis users in firearms cases. Gura stated in a 2025 podcast interview that "the government's position has always been incoherent—they claim cannabis users are too dangerous for guns but not too dangerous for freedom." He predicted that post-Bruen, courts will increasingly strike down the prohibition as applied to non-violent cannabis users, forcing comprehensive legislative reform. Drug policy expert Mark Kleiman, before his death in 2019, argued that the firearms prohibition was counterproductive because it incentivized cannabis users to lie on Form 4473, creating a culture of non-compliance. His research collaborator Beau Kilmer of RAND Corporation has continued this analysis, stating in 2025 testimony that "prohibition-era policies like the gun ban undermine respect for law and create selective enforcement risks." Law enforcement perspectives vary. The National Sheriffs' Association has maintained that cannabis users should be prohibited from firearms, citing officer safety concerns during traffic stops and domestic incidents. However, the Law Enforcement Action Partnership, representing current and former law enforcement officials who support drug policy reform, has argued that "cannabis use is not a proxy for dangerousness" and that the prohibition wastes enforcement resources. Veterans' advocates have been particularly vocal. Dr. Sue Sisley, a physician and researcher who has conducted FDA-approved studies of cannabis for PTSD in veterans, stated in 2024 congressional testimony that "forcing veterans to choose between their medicine and their Second Amendment rights is cruel and unnecessary." Sisley noted that many veterans use cannabis to reduce reliance on opioids and benzodiazepines, which carry greater impairment and overdose risks but do not trigger firearms prohibitions.

What's Next

The ATF form revision enters a 60-day public comment period ending July 14, 2026, followed by OMB review and final publication expected in August 2026, while parallel litigation and legislative efforts continue. The immediate timeline centers on the administrative process. ATF published the draft form for public comment on May 14, 2026, inviting input on the revised language and implementation questions. Industry groups, civil liberties organizations, and individual commenters are expected to submit thousands of comments addressing verification procedures, privacy concerns, and the continued prohibition on recreational users. Following the comment period, ATF will review submissions and may revise the form language before submitting it to OMB for Paperwork Reduction Act approval. OMB review typically takes 30-60 days. If the process proceeds on schedule, the final form could be published in August 2026, with an effective date 30 days later. However, significant public opposition or legal challenges could delay implementation. Several circuit court cases are pending that may be affected by the form revision. In United States v. Connelly, currently before the Tenth Circuit, a Colorado medical cannabis patient challenges his conviction under 18 U.S.C. § 922(g)(3) on Second Amendment grounds post-Bruen. The case was argued in March 2026, and a decision is expected by summer 2026. If the Tenth Circuit strikes down the prohibition as applied to medical users, it would create binding precedent across six states and potentially accelerate Supreme Court review. The Fifth Circuit's decision in United States v. Daniels, which held the prohibition unconstitutional as applied to a marijuana user, is currently on petition for certiorari to the Supreme Court. The Solicitor General's response is due in June 2026. If the Supreme Court grants review, oral argument would likely occur in the October 2026 term, with a decision by June 2027. A Supreme Court ruling could render the ATF form revision moot or require further revision depending on the scope of the holding. Congressional legislation remains stalled. The GRAM Act (Gun Rights and Marijuana Act), introduced in 2024, would amend 18 U.S.C. § 922(g)(3) to exempt cannabis users in states where use is legal. The bill has 47 House cosponsors from both parties but has not received committee action. Senate companion legislation has 12 cosponsors. Advocates note that gun rights and cannabis reform both have bipartisan support, but the combination remains politically challenging. The 2026 midterm elections may shift the legislative landscape. State-level developments will be critical. Several states including Pennsylvania and Florida are considering legislation to clarify that medical cannabis patients may obtain state firearms permits. However, these efforts face opposition from law enforcement groups and gun control advocates who argue that cannabis use and firearms are incompatible. Conversely, some states may maintain prohibitions even as federal policy shifts, creating a reverse preemption scenario where state law is more restrictive than federal law. The cannabis industry is watching whether the form revision accelerates broader federal reform. Industry advocates argue that acknowledging medical cannabis users' gun rights undermines the rationale for continued Schedule III restrictions and banking prohibitions. If medical cannabis users are safe to own firearms, the argument goes, they should also be able to access banking services and federal benefits. However, opponents note that gun rights and banking involve different policy considerations and legal frameworks. Enforcement priorities remain uncertain. The Department of Justice has not issued guidance on whether it will prosecute recreational cannabis users for firearms possession, particularly in states where recreational use is legal. Historically, federal firearms prosecutions have focused on individuals with prior criminal records or involvement in drug trafficking. Selective enforcement against otherwise law-abiding recreational users would be politically controversial and resource-intensive, but the legal authority remains. The DEA's rescheduling rule includes a five-year review